InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline. Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services,...
This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, as well as key rare genetic disease...
The TRANSCEND project aims to tackle the current limitations of drug development for Parkinson’s Disease by the integration of an innovative in vitro brain organoid model and a humanized in vivo mouse model. This unique two-step platform supports InnoSer’s aspiration...
As the InnoSer team, we are delighted to share the news – as of this week, we have a renewed vision and mission statement, as well as a renewed logo to accompany them. With these changes, we are ready more than ever not only for our continued growth and strong team...
Currently with no known cure, Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. InnoSer has recently finished a project with promising results in understanding altered...
Innoser is putting oncology development at the forefront of our efforts this year. By attending this year’s AACR 2021, we hope to improve our innovative oncology offerings and learn from the best. This year the American Association for Cancer Research is hosting...
